NeuroAiD(TM), A Stroke Treatment Based On Traditional Chinese Medicine, More Than Doubles The Chances Of Achieving Independence After Stroke
SINGAPORE, March 19, 2013 /PRNewswire/ -- Authors of a medical paper published in this month's Cerebrovascular Diseases journal found that NeuroAiD™, developed by Moleac, significantly improves patients' independence after suffering a stroke compared to other control groups. During the studies stroke patients taking NeuroAiD™ were twice as likely able to take care of themselves and speak freely. The study also showed that NeuroAiD™ improved patients' chances of performing daily activities after stroke.
Stroke is one of the leading causes of death worldwide and occurs every 2 seconds. Each year, 20 million people suffer from the devastating disease. There are only few effective, generally accepted and specific treatments for stroke, like thrombolytic treatment for highly selected patients. Therefore, there is an increasing need for multi-model therapies to help more patients recover quickly and effectively from stroke.
Herbal supplements have been demonstrated to have antioxidant, anti-inflammatory, and anti-glutamate effects, making them an attractive option to be investigated for stroke recovery. Thus, as Dr. Christopher Chen, one of the authors of the paper, says, "confirmation of the effectiveness of herbal supplements could have a great impact on stroke management". The paper updates the meta-analysis, published in Stroke journal in 2009 to include all clinical data available since 2009 on NeuroAiD™ and provides an overall assessment of the beneficial effects of NeuroAiD™ in improving functional and motor outcomes in the recovery after a stroke.
To address therapeutic gaps, Moleac has pioneered a new drug development approach, looking at sources of innovation from Traditional Medicines, hence shortening considerably drug development cycle time and investment to bring medicine to sufferers' unaddressed needs. Moleac's neurorestorative drug NeuroAiD™ reaches patients in more than 30 countries.Contact To learn more about the medical paper and for interview requests, please contact:
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts